Prevention of Postoperative Nausea and Vomiting

Wilhelm, Sheila M.; Dehoorne-Smith, Michelle; Kale-Pradhan, Pramodini

doi:10.1345/aph.1h398

Cited by 46 publications

(43 citation statements)

References 64 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,12 Nausea is an unpleasant sensation experienced in the back of the throat and epigastrum that may or may not result in the expulsion of contents from the stomach, while vomiting is the motor reflex resulting in forceful upward expulsion of contents from the stomach. 12,13 Retching involves the attempt to expel contents from the stomach without actually expelling them.…”

Section: Pathophysiology Of Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Janelsins¹,

Tejani²,

Kamen³

et al. 2013

Expert Opinion on Pharmacotherapy

134

110

View full text Add to dashboard Cite

Introduction Nausea and vomiting are two of the most frequent and troubling side effects patients experience during chemotherapy, interfering with compliance with cancer therapies and quality of life. While newly available treatments have improved our ability to manage nausea and vomiting, anticipatory and delayed nausea and vomiting are still major problems for patients receiving chemotherapy. Many cancer patients consider delaying future chemotherapy cycles and some contemplate stopping chemotherapy altogether because of their fear of experiencing further nausea and vomiting. Areas Covered The purpose of this article is to provide an overview of the patho-psychophysiology of chemotherapy-induced nausea and vomiting, the recommended guidelines for treatment, current agents in late-stage clinical trials, and future research needs to address the continued challenges of treatment-related nausea and vomiting. Expert Opinion Despite advances in pharmaceutical and behavioral therapies, and the provision of standard clinical guidelines for effectively managing chemotherapy-induced nausea and vomiting (CINV), patients continue to experience CINV. Moreover, control of nausea, acute and delayed, and anticipatory nausea and vomiting (ANV) remains an important, unmet need among cancer patients. It is critical to focus attention on better understanding the mechanisms underlying nausea, anticipatory symptoms, and delayed symptoms.

show abstract

Section: Pathophysiology Of Chemotherapy-induced Nausea and Vomitingmentioning

confidence: 99%

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Janelsins¹,

Tejani²,

Kamen³

et al. 2013

Expert Opinion on Pharmacotherapy

134

110

View full text Add to dashboard Cite

show abstract

“…5-HT3 receptor antagonists have been used since they were first proven to be highly effective in preventing postoperative nausea and vomiting [3]. Palonosetron is the most recently developed 5-HT3 antagonist and its efficacy was first proven in the prevention of chemotherapy induced nausea and vomiting (CINV).…”

Section: Introductionmentioning

confidence: 99%

The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting

Park

Jun

Lim

et al. 2012

Korean J Anesthesiol

View full text Add to dashboard Cite

Background5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are effective and safe on postoperative nausea and vomiting (PONV). Palonosetron, the newest 5-HT3 antagonist, has potent antiemetic property. We hypothesized that a combination of palonosetron and dexamethasone could more decrease PONV than palonosetron alone.MethodsAmong the patients scheduled to undergo laparoscopic gynecologic surgery, mastoidectomy with tympanoplasty or thyroidectomy under general anesthesia, eighty four female patients with at least two PONV risk factors were enrolled in this study. They were received randomly 0.075 mg palonosetron and 4 mg dexamethasone (group C) or 0.075 mg palonosetron alone (group P). The severity of PONV using Rhodes index and the percentage of complete response during postoperative 24 hours were compared between groups.ResultsThe frequency of mild/moderate/great/severe PONV based on Rhodes index were 9.8%/0%/0%/0% and 9.3%/2.3%/2.3%/0% in group P and group C, respectively. Complete response for PONV was observed in 90.2% and 86% of patients in group P and group C, respectively. The overall incidence of PONV in group P and C was 9.8% and 14%, respectively. There was no significant difference between the two groups.ConclusionsThere were no differences between palonosetron monotherapy and combination therapy of palonosetron and dexamethasone in patients with high emetogenic risk.

show abstract

“…[9] Drug like hyoscine, primarily used in motion sickness and have been found to be effective in control of PONV and dizziness following middle ear surgery. [310]…”

Section: Discussionmentioning

confidence: 99%

“…Hyoscine, a drug that controls motion sickness, was found to be effective in control of PONV in middle ear surgeries. [39] Many patients of middle ear surgery are noticed to complain of dizziness and vertigo in the intra and postoperative period and this could possibly be attributed to LFS and physical stimulation. There is considerable association between occurrences of vertigo-dizziness with nausea-vomiting in these cases.…”

Section: Discussionmentioning

confidence: 99%

Betahistine as an add-on: The magic bullet for postoperative nausea, vomiting and dizziness after middle ear surgery?

Mukhopadhyay

Niyogi

Ray

et al. 2013

J Anaesthesiol Clin Pharmacol

View full text Add to dashboard Cite

Purpose:Patients undergoing middle ear surgery experience variable degrees of postoperative nausea and vomiting (PONV) despite prophylaxis and treatment with ondansetron or other 5HT3 receptor antagonists. Furthermore vertigo or dizziness are not well controlled perioperatively. Role of betahistine was tested as an add-on to ondansetron in control of PONV and vertigo in middle ear surgery cases.Materials and Methods:We conducted a prospective, randomized, double-blind, placebo controlled study, enrolling one hundred patients undergoing middle ear surgery under local anesthesia into two groups consisting of fifty (n = 50) patients each. Group A patients were given betahistine 16 mg plus ondansetron 8 mg and placebo plus ondansetron 8 mg were given to group B or placebo group, orally 3 hours before starting operation. The incidence of nausea, vomiting, and dizziness was noted during the intraoperative and postoperative 24 hours period. Chi-square test, unpaired ‘t’ test, and Fisher’s exact tests were performed for statistical analysis using SPSS version 16 and Open Epi version 2.3.1 softwares.Results:Complete response was obtained in 90% patients in the betahistine group as compared to 66% in the placebo group. Vomiting in the intraoperative and postoperative period was noted in 4% and 8% cases, respectively, in the betahistine group as compared to 18% and 26%, respectively, in the placebo group. Overall, vertigo was 10% versus 32% in betahistine group and placebo group, respectively.Conclusion:Betahistine as an add-on to ondansetron can significantly attenuate PONV and perioperative vertigo, following middle ear surgeries.

show abstract

Prevention of Postoperative Nausea and Vomiting

Cited by 46 publications

References 64 publications

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients

The comparative study to evaluate the effect of palonosetron monotherapy versus palonosetron with dexamethasone combination therapy for prevention of postoperative nausea and vomiting

Betahistine as an add-on: The magic bullet for postoperative nausea, vomiting and dizziness after middle ear surgery?

Contact Info

Product

Resources

About